65,437 trials
Recurrent Melanoma · Stage IIIA Melanoma · Stage IIIB Melanoma
Primary: Number of Subjects With Objective Response(Partial Response and Complete Response) as Measured by RECIST Criteria — 2 participants
Primary Open Angle Glaucoma · Healthy Subjects
Primary: SENSIMED Triggerfish Efficacy — 56.9 mV/h
Multiple Myeloma
Primary: Phase I - Maximum Planned Dose (MPD) Level — 4 Dosing Level
Breast Cancer · Brain Metastases
Primary: The Maximum Tolerated Dose of Lapatinib When Combined With Cranial Radiation in Patients With CNS Metastases From HER2-positive Breast Cancer. — 1250 milligrams
Major Depressive Disorder
Primary: Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17) at Week 8 — -9.71; -11.28; -11.67 Units on a scale — p=0.006
Fatty Liver
Primary: Percent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels — -0.68; -0.28; 0.65; 6.36 percentage change — p=0.222
Cooperative Behaviour · Dental Anxiety
Primary: Behaviors of Children — 0.97; 1.09; 2.95; 2.98 units on a scale
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
Estrogen Receptor-negative Breast Cancer · Male Breast Cancer · Progesterone Receptor-negative Breast Cancer
Primary: Disease Control Rate (DCR) — 0 participants
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Number of Participants With or Without Progression-free Survival for > 6 Months by Response Evaluation Criteria for Solid Tumors (RECIST) — 39; 11 participants
Coronary Artery Disease · Coronary Heart Disease · Dyslipidemia
Primary: Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT) — -0.006; 0.000 mm/year — p=0.220
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
Hepatitis C, Chronic
Primary: The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12) — 91.7; 100.0; 38.5 Percentage of Participants
Nonmalignant Neoplasm · Prostate Cancer
Primary: Change in Extent of Cancer — 3; 2; 4 participants
Lymphoproliferative Disorder
Primary: Event-free Survival — 71 percentage of participants analyzed